N/A N=25 EU Post Market Clinical Follow-Up Study of the Venclose System for Saphenous Vein Incompetence
Chronic Venous Insufficiency
Primary: Vein Occlusion Rate — 29; 0; 0 limbs
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=69 ClosureFAST vs. Laser Ablation for the Treatment of GSV Disease: A Multicenter, Single-Blinded, Randomized Study.
Venous Reflux
Primary: Pain — 0.7; 1.9 units on a scale — p=<0.0001
N/A N=242 VenaSeal Sapheon Closure System Pivotal Study (VeClose)
Great Saphenous Vein (GSV) With Venous Reflux Disease
Primary: Number of Participants With Complete Closure of the Target Vein at 3 Months — 107; 109 Participants — p=<0.0001
Phase 3 N=117 Endovenous Ablation With and Without Polidocanol Endovenous Microfoam Treatment for Patients With Great Saphenous Vein Incompetence and Visible Varicosities
Great Saphenous Vein Incompetence · Visible Varicosities
Primary: Absolute Change From Baseline in Independent Photography Review (IPR-V3 Score) — -0.80; -1.30; -1.11 score
N/A N=293 The Long-term Value of Preoperative Duplex Before Surgery for Varicose Veins
Varicose Veins
Primary: Rate of Re-do Surgery — 15; 38 legs
Phase 3 N=279 Efficacy and Safety Study of Polidocanol Injectable Foam for the Treatment of Saphenofemoral Junction (SFJ) Incompetence
Varicose Veins
Primary: Change in Patient-reported Symptoms of Varicose Veins (VVSymQ Score) — 2.13; 4.63; 5.68; 4.87 units on a scale — p==0.0001
N/A N=326 ClosureFAST - Radiofrequency Great Saphenous Vein Treatment
Venous Reflux
Primary: Percentage of Limbs Without Vein Occlusion — 97.6 percentage of limbs
N/A N=450 Early Venous Reflux Ablation Ulcer Trial
Venous Leg Ulcer
Primary: Time to Ulcer Healing From Date of Randomisation to Date of Healing up to 365 Days — 82; 56 days
N/A N=72 Preventing Seroma Formation After Stripping Saphenous Vein in Coronary Bypass
Coronary Bypass Graft Stenosis of Autologous Vein
Primary: Early Complications of Vascular Zone — 1; 4; 15; 5 participants — p=0.05
Phase 4 N=200 Radiofrequency Ablation vs Laser Ablation of the Incompetent Greater Saphenous Vein
Chronic Venous Insufficiency
Primary: Percentage of Participants Without Recurrent Clinical Symptoms of an Incompetent Greater Saphenous Vein After Treatment. — 79.3; 77.5 percentage of total participants
N/A N=1,150 Randomized Endo-Vein Graft Prospective
Coronary Artery Bypass Grafting
Primary: Incidence of First MACE During Active Follow-up Period. — 80; 89 Participants — p=0.47
Phase 3 N=235 Polidocanol Endovenous Microfoam (PEM) Versus Vehicle for the Treatment of Saphenofemoral Junction (SFJ) Incompetence
Varicose Veins
Primary: Change in Patient-Reported Symptoms of Varicose Veins (VVSymQ Score) — -2.00; -5.34; -6.01; -5.06 units on a scale — p=<0.0001
N/A N=18 Influence of Flat-knitted Compression Stockings Class I and II on Venous Malformations
Vascular Malformations · Vascular Malformation Peripheral · Venous Malformation
Primary: Volume Difference of Malformation to Baseline (no Compression) While Wearing Compression Stockings Class I and II Determined by MRI — 16.38; 23.7 ml
N/A N=19 Endothelial Function in Lower Extremity Bypass Grafts
Peripheral Arterial Disease
Primary: Change From Baseline in Saphenous Vein Bypass Graft Vasodilation — 5.28 vein bypass graft size increase (%)
Phase 4 N=148 GORE VIABAHN ENDOPROSTHESIS Peripheral Vascular Disease Study
Peripheral Vascular Diseases
Primary: Efficacy: Primary Patency at Three Years — 24.2; 25.9 percentage of subjects
N/A N=200 ABRE Clinical Study of the Abre Venous Self-expanding Stent System
Iliofemoral Venous Obstruction
Primary: Primary Patency — 162 Participants — p=<0.0001
N/A N=27 Venclose RF Ablation System for the Treatment of IPVs
Chronic Venous Insufficiency
Primary: Safety: AEs, SAEs, ADEs, SADEs, UADEs — 0; 0; 0; 0 Events
N/A N=40 Venous Insufficiency and Neuromuscular Stimulation
Chronic Venous Disease · Venous Insufficiency · Deep Venous Obstruction
Primary: Percentage Change of Haemodynamic Flow — 34.8; 62.8; 9; 14.8 % change
N/A N=22 REVITIVE for the Treatment of Patients With Venous Insufficiency
Venous Insufficiency · Oedema · Varicose Veins
Primary: Venous Haemodynamics - Percent Change in Time Averaged Mean Velocity TAMV — 102.4; -9.1 percentage change — p=0.001
N/A N=76 Effect of VarIthena on Wound Healing in Venous Leg Ulcers (VLU)
Venous Leg Ulcer
Primary: Change From Baseline in Wound Perimeter — 29.36; 43.64 mm
N/A N=162 Venous Stent for the Iliofemoral Vein Investigational Clinical Trial Using the DUO Venous Stent System
May-Thurner Syndrome · Deep Vein Thrombosis · Chronic Venous Insufficiency
Primary: Safety - Number of Participants Free From Major Adverse Events (MAEs) at 30 Days — 157 Participants
N/A N=407 Intermittent Pneumatic Compression in Surgical Patients at Extremely-high Risk for Venous Thromboembolism
Venous Thromboembolism · Venous Thrombosis
Primary: Number of Patients With Asymptomatic Venous Thrombosis of Lower Limbs as Detected by Duplex Ultrasound — 1; 34 Participants — p=<0.001
N/A N=4 A Clinical Evaluation of the Treatment of Spider Veins on the Ankles
Spider Veins
Primary: Physician Global Assessment of Improvement in Treated Spider Veins on the Ankles — 3.7 score on a scale
N/A N=204 Compression Therapy Following Endothermal Ablation
Varicose Veins
Primary: Patient's Post-procedure Pain Score Using a Visual Analogue Scale (VAS) — 18.7; 27.8 mm
N/A N=43 Safety and Efficacy of Endovenous Laser Ablation for the Resolution of Incompetent Perforator Veins
Venous Insufficiency
Primary: Primary Effectiveness Objective — 53; 66 Treated IPVs
Phase 4 N=81 Treatment of Chronic Deep Vein Thrombosis (DVT) and Post-Thrombotic Syndrome (PTS) With the EkoSonic® Endovascular System
Deep Vein Thrombosis · Post-thrombotic Syndrome
Primary: Change From Baseline in Villalta Score at Day 30 Post-EkoSonic® Study Treatment Procedure — 15.5; -5.9 units on a scale
N/A N=124 GORE® VIABAHN® Endoprosthesis Post-Marketing Surveillance Study
Vascular Stent-Graft Stenosis
Primary: Number of Subjects With Loss of Primary Patency of Target Lesion — 81 Participants
Phase 3 N=77 Randomized, Single Blind, Placebo Controlled, to Evaluate Efficacy and Safety of Polidocanol Injectable Foam for Treatment of Symptomatic, Visible Varicose Veins With SFJ Incompetence
Varicose Veins
Primary: The Absolute Change From Baseline Score for the VVSymQ (Total Score) at 8 Weeks — 16.7; 30.7 units on a scale
Phase 3 N=537 Pivotal Trial of Dermagraft(R) to Treat Venous Leg Ulcers
Venous Leg Ulcer
Primary: Complete Healing of the Study Ulcer by Week 16. — 201; 176 participants — p=0.1030
N/A N=112 SeCure Endovenous Laser Treatment Study
Chronic Venous Insufficiency
Primary: Acute Primary Ablation Success — 96 Veins